Vericel (VCEL) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Vericel (VCEL) do?
Vericel Corp (VCEL) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Harvests patient cells to manufacture custom cartilage implants and severe burn treatments. Manufactures custom cell therapies for knee cartilage repair and severe burns using patient tissues. It is worth $2.97B on the market and sold $324.21M over the last year.
- Market cap
- $2.97B
- P/E ratio
- 92.2×
- Annual sales
- $324.21M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 15, 2026
Brands and businesses behind VCEL
- MACI: An autologous cellular implant that repairs knee cartilage damage, generating revenue per patient surgical procedure.
- Epicel: A personalized cultured skin graft that treats severe deep dermal burns, sold directly to specialized burn centers.
- NexoBrid: A topically applied enzyme biologic that removes dead tissue from severe burns, earning through hospital sales.
VCEL’s flags, in plain English
Each flag is a number from Vericel’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.
Stupid Cash
Can pay this year's bills 5.1 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 74.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earnings Jumping
Profits up 137.2% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.
Priced for Perfection
Priced at 92.2 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about VCEL
How big is Vericel?
Vericel’s market cap is $2.97B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $324.21M: what customers paid the company over the last year, before any costs.
What is VCEL’s P/E ratio?
VCEL’s P/E ratio is 92.2×. Investors pay about 92.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with VCEL?
Revenue depends heavily on commercial health insurers and government programs agreeing to pay for high-cost custom cell therapies. That is one risk on Vericel’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Vericel’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. VCEL’s filings on SEC.gov. The Margin Monkey is research, not advice.
